Local Administration of Methylcobalamin and Lidocaine for Acute Ophthalmic Herpetic Neuralgia: A Single-Center Randomized Controlled Trial

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Based on the onset, patients with AOHN (n = 98) were randomly allocated into groups A (≤ 3 days) and B (4 to 7 days) and then subdivided into control (A0, B0; received intramuscular methylcobalamin in addition to local lidocaine injection) and treatment (A1, B1; received local injection of the methylcobalamin and lidocaine combination for 14 days) groups.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A time span of 14 days appears in the methods.

Multilevel modeling and survival analysis were performed.

What Was Measured

PubMed files the paper under topics including Anesthetics, Local, Herpes Zoster Ophthalmicus, Incidence, Lidocaine, Neuralgia, Postherpetic, Quality of Life and Vitamin B 12.

Author keywords: acute ophthalmic herpetic neuralgia, methylcobalamin, randomized clinical trial and subcutaneous injection.

What This Means in Plain Language

The paper is a randomized study of Cyanocobalamin (Vitamin B12) over 14 days.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Pain practice : the official journal of World Institute of Pain), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.